Tri- Or Tetrasaccharide Patents (Class 514/61)
  • Patent number: 10111895
    Abstract: The invention discloses novel endocrine treatment phytochemicals which affect androgenic status. The method for treatment of 5-alpha-reductase responsive diseases using four novel 5-alpha-reductase inhibitor compounds; leucoanthocyanidin, glabrene, glabridin, and alpha-terpineol is disclosed. Glabridin does not interfere with normal testosterone to androgen receptor binding.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: October 30, 2018
    Inventor: Suzanne Janine Paxton-Pierson
  • Patent number: 9066968
    Abstract: The present invention has an object to provide a fluid for peritoneal dialysis with satisfactory body fluid removability, high biocompatibility, and improved storage stability, and the object is attained by a fluid for peritoneal dialysis containing one or more saccharides selected from cyclonigerosylnigerose, cyclomaltosylmaltose, and L-ascorbic acid 2-glucoside.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: June 30, 2015
    Assignee: HAYASHIBARA CO. LTD
    Inventors: Hitomi Ohta, Toshiharu Hanaya, Shigeharu Fukuda, Yoshikatsu Miwa, Toshio Miyake
  • Patent number: 9034847
    Abstract: A method of inhibiting inflammation in a subject comprising the administration of milk oligosaccharides or glycoconjugates containing milk oligosaccharides is disclosed.
    Type: Grant
    Filed: July 2, 2010
    Date of Patent: May 19, 2015
    Assignees: Children's Hospital Medical Center, The General Hospital Corporation, Instituto Nacional de Ciencias Medicas Y Nutricion
    Inventors: Ardythe L. Morrow, David S. Newburg, Guillermo M. Ruiz-Palacios
  • Publication number: 20150119360
    Abstract: The present invention provides a growth promoting composition capable of promoting growth of a microorganism belonging to the genus Bifidobacterium living in the intestine of mammals such as human and the like. According to the present invention, a composition for promoting growth of a microorganism belonging to the genus Bifidobacterium, comprising one or more kinds selected from the group consisting of Lacto-N-tetraose, Lacto-N-neotetraose and derivatives thereof can be provided. The aforementioned growth promoting composition is suitable for promoting growth of the aforementioned microorganism in the intestine by oral administration to, particularly, a human adult.
    Type: Application
    Filed: April 23, 2013
    Publication date: April 30, 2015
    Inventors: Kenji Yamamoto, Satoshi Koizumi
  • Publication number: 20150119353
    Abstract: The present teachings provide new compositions comprising polycations and polycations, and the preparation and use of these new compositions, In one aspect, the new compositions are complex coacervates. The compositions described herein can have several desired properties, including, low interfacial tension in water, adjustable cohesive strength, antimicrobial activity, suitability for dissolution at or near physiological pH, the ability to promote cell attachment, biocompatiblility, and/or biodegradability. Thus, in various embodiments, the complex coacervates can be used in water-based applications, for example, in the body.
    Type: Application
    Filed: February 21, 2013
    Publication date: April 30, 2015
    Inventor: Neal Vail
  • Publication number: 20150087616
    Abstract: Provided are methods and pharmaceutical compositions for treating symptoms associated with lactose intolerance and for overall improvement in gastrointestinal health. Described herein are methods and pharmaceutical compositions for improving overall gastrointestinal health or for decreasing symptoms of lactose intolerance by administering to subject in need thereof a pharmaceutical composition comprising a prebiotic, optionally in combination with effective amount of a probiotic microbe or microbes.
    Type: Application
    Filed: November 30, 2012
    Publication date: March 26, 2015
    Inventors: Andrew J. Ritter, Dennis Savaiano, David Barnes, Todd Klaenhammer
  • Publication number: 20150079055
    Abstract: An individual at risk for necrotizing enterocolitis and related disorders can be identified by measuring the level of at least one secretor antigen in a biological sample from the individual and comparing the measured level of the at least one secretor antigen to a predetermined value or a predetermined range of values. Among the secretor antigens which can be measured are: the H-1, H-2, Lewisb and Lewisy antigens and derivatives thereof (e.g., a sialylated form of Lewis a, Lewis x, Lewis b, Lewis y; H-1, H-2, Lewis a, Lewis x, Lewis b or Lewis y).
    Type: Application
    Filed: September 23, 2014
    Publication date: March 19, 2015
    Applicants: Children's Hospital Medical Center, The General Hospital Corporation, Instituto Nacional de Ciencias Medicas Y Nutricion
    Inventors: Ardythe L. Morrow, David S. Newburg, Guillermo M. Ruiz-Palacios
  • Patent number: 8962032
    Abstract: There is provided a method for suppressing a pro-inflammatory immune response in a cell, comprising providing to a cell sialic acid or analogs thereof, wherein the sialic acid or analogs are presented by a substrate such that a pro-inflammatory immune response in a cell is suppressed or an anti-inflammatory immune response is increased in a cell. Further, there is provided a method of treatment of inflammatory disease in a subject in need thereof. There is also provided a drug delivery device and a biomaterial which can modulate the inflammatory response in a subject.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: February 24, 2015
    Assignee: The Queen's University of Belfast
    Inventors: Christopher Scott, James Johnston, Shaun Spence, Danny McAuley, Francois Fay
  • Patent number: 8961953
    Abstract: This invention relates to a preparation comprising N-acetyl-lactosamine and/or an oligosaccharide containing N-acetyl-lactosamine and a probiotic Lactobacillus sp. The invention extends to nutritional compositions comprising said preparation and to the use of the preparation in the prevention and treatment of pathogenic infections of the gastro-intestinal and upper respiratory tracts.
    Type: Grant
    Filed: February 24, 2009
    Date of Patent: February 24, 2015
    Assignee: Nestec S.A.
    Inventor: Norbert Sprenger
  • Patent number: 8951992
    Abstract: The present invention is directed to methods and compounds for inhibiting bacterial growth and treating a bacterial infection in a subject. These methods involve providing an inhibitor of intrabacterial pH homeostasis, including inhibitors of the Mycobacterium tuberculosis Rv3671c gene encoded membrane protease. Methods for identifying novel compounds that disrupt intrabacterial pH homeostasis and their use for inhibiting bacterial growth and treating a bacterial infection in a subject are also disclosed.
    Type: Grant
    Filed: July 20, 2009
    Date of Patent: February 10, 2015
    Assignee: Cornell University
    Inventors: Carl Nathan, Sabine Ehrt, Omar Vandal, Crystal Darby
  • Publication number: 20150031645
    Abstract: Disclosed are nutritional compositions including human milk oligosaccharides that can be administered to preterm infants, term infants, toddlers, and children for improving airway defense mechanisms.
    Type: Application
    Filed: August 11, 2014
    Publication date: January 29, 2015
    Applicant: ABBOTT LABORATORIES
    Inventors: RACHAEL BUCK, GERALYN O. DUSKA-MCEWEN, STEVEN R. DAVIS
  • Patent number: 8940325
    Abstract: The present invention relates to the use of at least one compound selected among the synthetic polysulphated oligosaccharides having 1 to 4 ose units and to the salts and complexes thereof as cleaning agents for a wound. The invention can be used in particular for preparing bandages intended for cleaning wounds.
    Type: Grant
    Filed: February 16, 2011
    Date of Patent: January 27, 2015
    Assignee: Laboratories Urgo
    Inventors: Laurent Apert, Christelle Laurensou, Dominque Nicot
  • Patent number: 8940715
    Abstract: The object of the present invention is to provide a lipid-regulating agent or a composition for regulating the amount of lipids comprising the agent. The present invention solves the above object by providing a lipid-regulating agent comprising a cyclic tetrasaccharide and/or its saccharide-derivative(s) and a composition for regulating the amount of lipids comprising the lipid-regulating agent.
    Type: Grant
    Filed: February 19, 2008
    Date of Patent: January 27, 2015
    Assignee: Hayashibara Co., Ltd.
    Inventors: Kazuyuki Oku, Michio Kubota, Shigeharu Fukuda, Toshio Miyake
  • Publication number: 20150010509
    Abstract: Disclosed herein are methods for the treatment of cancer and inflammatory-based diseases and disorders, such as hepatitis B virus infection, tuberculosis and type 2 diabetes based upon the administration of CaFolate. In one embodiment is a method of treating cancer comprising administration of CaFolate. In another embodiment is a method of treatment inflammatory-based disease and disorders comprising administration of CaFolate.
    Type: Application
    Filed: January 29, 2013
    Publication date: January 8, 2015
    Applicant: SanRx Pharmaceuticals, Inc.
    Inventor: Phillip Moheno
  • Publication number: 20150011470
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, Z, A1, L and A2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Application
    Filed: September 19, 2014
    Publication date: January 8, 2015
    Applicant: PFIZER INC.
    Inventors: Mary Theresa Didiuk, Robert Lee Dow, David Andrew Griffith
  • Publication number: 20150011488
    Abstract: Epicatechins, Epicatechin Oligomers, or Thiolated Epicatechins are applied (A) directly to a genital wart in the form of a cream, ointment, paste or solution, (B) directly to the genital wart wherein such cream, ointment, paste or solution contains as an additional active ingredient a skin permeabilizing agent, (C) following electrosurgical resection or removal of the genital wart in such form of a cream, ointment, paste or solution, (D) following chemical resection or extirpation of the genital wart in such form, (E) following surgical resection or removal of the genital wart in such form, wherein said Epicatechins, Epicatechin Oligomers, or Thiolated Epicatechins both provide antiviral activity against multiple strains of human pappilomavirus (HPV) and promote healing following resection polymers contained in a vehicle. Disclosed are the compositions, therapeutical kits containing such composition, methods of treatment using such composition, and methods of enhancing the stability of such composition.
    Type: Application
    Filed: March 10, 2014
    Publication date: January 8, 2015
    Applicant: CACAO BIO-TECHNOLOGIES, LLC
    Inventors: Daniel PRESTON, Randall B. MURPHY
  • Patent number: 8927504
    Abstract: The present invention provides a novel therapeutic or preventive method, a pharmaceutical composition and use thereof, that exhibit superior anti-obesity effects (body weight-reducing (losing) effects and/or body fat mass-reducing effects). Specifically, the present invention provides a pharmaceutical composition comprising the combination of a dipeptidyl peptidase 4 inhibitor and a sweetener having a GLP-1 secretion-stimulating action, as well as use thereof for the manufacture of a medicament. The present invention also provides a method for treating or preventing obesity, comprising administering an effective amount of (a) a dipeptidyl peptidase 4 inhibitor and (b) a sweetener having a GLP-1 secretion-stimulating action to a patient suffering from symptoms of obesity.
    Type: Grant
    Filed: April 3, 2008
    Date of Patent: January 6, 2015
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Masaharu Shiotani, Tomomi Ishihara, Chiaki Matsushita
  • Patent number: 8921339
    Abstract: Apparatus for contacting body fluids with the bio-affinity material is disclosed. The apparatus includes a container having top and bottom lock covers that clip onto the container.
    Type: Grant
    Filed: August 15, 2007
    Date of Patent: December 30, 2014
    Assignee: Glycorex Transplantation AB
    Inventor: Kurt Nilsson
  • Publication number: 20140378415
    Abstract: The present invention provides compounds of formula (I) wherein P is P0, heterocyclyl or heterocyclyl substituted by one to five Z formula (II); Y1, Y2, Y3 and Y4 are independently of each other C—H, C—R5, or nitrogen; G1 is oxygen or sulfur; X4 is C1-C8 haloalkyl; R4 is aryl or aryl substituted by one to five R9, or heteroaryl or heteroaryl substituted by one to five R9; and R1, R2, R4, R5, R9 and Z are as defined in the claims. The invention also provides compositions comprising the compounds of formula (I), intermediates useful in the preparation of compounds of formula (I) and methods of using the compounds of formula (I) to control insects, acarines, nematodes or molluscs.
    Type: Application
    Filed: August 27, 2012
    Publication date: December 25, 2014
    Applicant: SYNGENTA PARTICIPATIONS AG
    Inventors: Jerome Yves Cassayre, Myriem El Qacemi
  • Publication number: 20140371173
    Abstract: A prebiotic formulation for oral administration to a human comprising 2?-fucosyllactose, 3?-sialyllactose and 6?-sialyllactose, and a method for modulating or stimulating the growth of Bifidobacteria in the gut. The formulation may be an infant formula.
    Type: Application
    Filed: February 3, 2012
    Publication date: December 18, 2014
    Applicant: NESTEC S.A.
    Inventor: David Curtis Frantz
  • Patent number: 8906891
    Abstract: This process relates to a pharmaceutical composition of an Na—K-ATPase ligand which will stimulate Na/K-ATPase signaling in a pharmaceutically acceptable vehicle. In one embodiment, the composition may be used to treat a skin disorder. In another embodiment, the composition may be used to inhibit cardiac fibrosis.
    Type: Grant
    Filed: January 30, 2007
    Date of Patent: December 9, 2014
    Assignee: The University of Toledo
    Inventors: Zijian Xie, Joseph I. Shapiro
  • Publication number: 20140349923
    Abstract: Compositions are disclosed which comprise one or more of the following; an anthocyanin, an oligosaccharide, a pectin, or a long-chain fatty acid. Such compositions are useful for treating diabetes or obesity.
    Type: Application
    Filed: January 14, 2013
    Publication date: November 27, 2014
    Inventors: Mark Andrew Paulik, Rebecca Jane Hodge
  • Publication number: 20140343014
    Abstract: The present invention relates to the use of a combination of a certain DPP-4 inhibitor and an alpha-glucosidase inhibitor for use in therapy, e.g. for use in treating and/or preventing a metabolic disease such as type 2 diabetes mellitus and/or conditions related thereto. The invention also relates to the use of such combination for improving body weight control, reducing body weight, inducing satiety, inhibiting gastric emptying and/or reducing food intake, in a patient in need thereof.
    Type: Application
    Filed: May 16, 2014
    Publication date: November 20, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Thomas KLEIN, Michael MARK
  • Publication number: 20140308272
    Abstract: According to the present invention, treatment of prion protein related diseases, and in particular cancer tumours, is effected by providing to a subject in need thereof a therapeutically effective amount of an agent capable of modulating binding of a prion protein and/or a prion-like protein to a disease related GAG and/or HSPG.
    Type: Application
    Filed: January 17, 2014
    Publication date: October 16, 2014
    Applicant: Sylvan Pharmaceuticals Pty, Ltd.
    Inventors: John Fergus McEwan, David Cullis-Hill, Martin Lyndale Windsor
  • Patent number: 8846613
    Abstract: The invention relates to a pharmaceutical composition comprising 1.a and/or 1.b according to claim 1 in combination with at least one second therapeutic agent 2 which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: September 30, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Bradford S. Hamilton, Thomas Rauch, Manami Tsutsumi
  • Patent number: 8846642
    Abstract: A nutritional composition for administration to an infant which composition comprises, on a dry matter basis, from 2.5 to 15.0 wt % of an oligosaccharide mixture consisting of N-acetylated oligosaccharide(s), galacto-oligasaccharide(s) and sialylated oligosaccharide(s) with the proviso that the composition comprises at least 0.02 wt % of an N-acetylated oligosaccharide, at least 2.0 wt % of a galacto-oligosaccharide and at least 0.04 wt % of a sialylated oligosaccharide and that the N-acetylated oligosaccharide(s) comprise 0.5 to 4.0% of the oligosaccharide mixture, the galacto-oligosaccharide(s) comprise 92.0 to 98.5% of the oligosaccharide mixture and the sialylated oligosacchardide(s) comprise 1.0 to 4.0% of the oligosaccharide mixture. The composition is useful for administration to an infant in the first six months of life to reduce the risk of obesity later in life.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: September 30, 2014
    Assignee: Nestec S.A.
    Inventors: Marie-Claire Fichot, Norbert Sprenger, Francois-Pierre Martin, Sunil Kochhar, Serge Rezzi
  • Publication number: 20140286931
    Abstract: The present invention relates to new biphenyl-3-carboxylic acid modulators of beta-3-adrenoceptor activity, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: June 5, 2014
    Publication date: September 25, 2014
    Inventor: Chengzhi Zhang
  • Patent number: 8841279
    Abstract: The invention provides a pharmaceutical composition comprising a macromolecular drug and an oligoguluronate or oligogalacturonate, e.g., having a number average degree of polymerization in the range 5 to 18, a guluronate (or galacturonate) fraction (FG) of at least 0.80, a mannuronate fraction (FM) of no more than 0.20, and having at least 95% mole with a degree of polymerization less than 20. The composition may be used in a method of treatment which comprises administering the composition to a mucosal surface in a human or non-human vertebrate subject.
    Type: Grant
    Filed: April 11, 2008
    Date of Patent: September 23, 2014
    Assignee: Norwegian University of Science and Technology
    Inventors: Catherine Taylor, Kurt Ingar Draget, Olav Asmund Smidsrod
  • Patent number: 8841427
    Abstract: Methods to introduce highly phosphorylated mannopyranosyl oligosaccharide derivatives containing mannose-6-phosphate (M6P), or other oligosaccharides bearing other terminal hexoses, to carbonyl groups on oxidized glycans of glycoproteins while retaining their biological activity are described. The methods are useful for modifying glycoproteins, including those produced by recombinant protein expression systems, to increase uptake by cell surface receptor-mediated mechanisms, thus improving their therapeutic efficacy in a variety of applications.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: September 23, 2014
    Assignee: Genzyme Corporation
    Inventor: Yunxiang Zhu
  • Patent number: 8835403
    Abstract: The present invention provides an alginate oligosaccharide and its derivatives with the degree of polymerization ranging from 2 to 22. The alginate oligosaccharide is composed of ?-D-mannuronic acid linked by 1,4 glycosidic bonds. The derivatives with the reduced terminal in position 1 of carboxyl radical can be prepared by oxidative degradation. The present invention also provides a process for preparing the alginate oligosaccharide and its derivatives, which includes the procedures that an alginate solution is reacted for 2 to 6 h in an autoclave at pH 2-6 and the temperature of 100-120° C., and pH is adjusted to 7 after the reaction is stopped, after which the resultant oligosaccharide is oxidized in the presence of an oxidant to obtain an oxidative degradation product. The alginate oligosaccharide and its derivatives of the invention can be used in the manufacture of a medicament for the prophylaxis and treatment of AD and diabetes.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: September 16, 2014
    Inventors: Meiyu Geng, Huashi Guan, Xianliang Xin, Zhao Yang, Guangqiang Sun
  • Publication number: 20140249103
    Abstract: Disclosed are nutritional compositions including human milk oligosaccharides that can be administered to individuals including preterm infants, infants, toddlers, and children for improving gastrointestinal function and tolerance, as well as the growth of beneficial bacteria. Additional suitable methods of using the nutritional compositions including the human milk oligosaccharides are also disclosed.
    Type: Application
    Filed: March 6, 2014
    Publication date: September 4, 2014
    Inventors: RACHAEL BUCK, JOMAY CHOW, STEVEN R. DAVIS
  • Patent number: 8815522
    Abstract: The present invention provides umbrella-topology glycan decoys. The present invention provides systems and methods treating influenza infection utilizing inventive umbrella-topology glycan decoys. The present invention provides methods for identifying novel umbrella-topology glycan decoys.
    Type: Grant
    Filed: January 2, 2009
    Date of Patent: August 26, 2014
    Assignee: Massachusetts Institute of Technology
    Inventors: Ram Sasisekharan, Karthik Viswanathan, Aarthi Chandrasekaran, Rahul Raman, Aravind Srinivasan, S. Raguram, Viswanathan Sasisekharan
  • Patent number: 8815831
    Abstract: The invention provides a method to improve the efficacy of an antibiotic to inhibit the growth of Acinetobacter, said method comprising using said antibiotic together with an alginate oligomer. The Acinetobacter may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides an alginate oligomer for use together with at least one antibiotic in treating a subject infected, suspected to be infected, or at risk of infection, with Acinetobacter. In another aspect the method can be used to combat Acinetobacter contamination of a site e.g., for disinfection and cleaning purposes.
    Type: Grant
    Filed: June 3, 2010
    Date of Patent: August 26, 2014
    Assignee: Algipharma AS
    Inventors: Edvar Onsoyen, Rolf Myrvold, Arne Dessen, David Thomas, Timothy Rutland Walsh
  • Publication number: 20140235575
    Abstract: The present invention provides a one-pot multi-enzyme method for preparing UDP-sugars from simple sugar starting materials. The invention also provides a one-pot multi-enzyme method for preparing oligosaccharides from simple sugar starting materials.
    Type: Application
    Filed: January 21, 2014
    Publication date: August 21, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Xi Chen, Hai Yu, Yanhong Li, Yi Chen, Jingyao Qu, Musleh M. Muthana, Kam Lau, Lars Bode
  • Patent number: 8802841
    Abstract: A 1,2-dideoxy-1,2-diamino oligosaccharide or polysaccharide in its free base, salt or metal-complex form as shown in General Formula 1 and derivative thereof is described. R1, R2 and R3 are each independently selected from the group consisting of H and a carbohydrate moiety, with the proviso that at least one of the groups R1, R2 or R3 is a carbohydrate moiety; R4 is selected from the group consisting of: H, optionally substituted C1-20-alkyl, optionally substituted heteroalkyl, optionally substituted C2-20-alkenyl, optionally substituted C2-20-alkynyl, optionally substituted C3-10-cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl.
    Type: Grant
    Filed: November 3, 2008
    Date of Patent: August 12, 2014
    Assignee: Glycom A/S
    Inventors: Gyula Dekany, István Bajza, Marie Bøjstrup, Károly Ágoston, Lars Kröger, Ignacio Figueroa Pérez, Christoph H. Röhrig, Paulo Vital, Erzsébet Czinege
  • Publication number: 20140213530
    Abstract: This disclosure demonstrates that inhibition of Sirt5 can suppress malignant transformation of cells. Therefore, methods of treating cancer based on inhibition of Sirt5 are disclosed.
    Type: Application
    Filed: September 7, 2012
    Publication date: July 31, 2014
    Applicant: CORNELL UNIVERSITY
    Inventors: Hening Lin, Richard Cerione
  • Patent number: 8754064
    Abstract: The present invention relates to methods and nutritional compositions for stimulating the immune system, particularly in subjects with an impaired immune system such as 5 infants, said method comprising administering a composition comprising sheep milk and/or short chain oligosaccharides.
    Type: Grant
    Filed: March 21, 2007
    Date of Patent: June 17, 2014
    Assignee: N.V. Nutricia
    Inventors: Laura M'Rabet, Antonie Van Baalen, Bernd Stahl, Arjan Paul Vos, Thomas Hubertus Martinus Snoeren
  • Patent number: 8754063
    Abstract: A method of treatment of a human or non-human subject to combat mucosal hyperviscosity in the respiratory tract, which method includes application to a mucosal surface in the tract in the subject of an effective amount of a physiologically tolerable oligouronate. Related compositions containing physiologically tolerable oligouronates are also described.
    Type: Grant
    Filed: October 6, 2006
    Date of Patent: June 17, 2014
    Assignee: NTNU Technology Transfers AS
    Inventors: Catherine Taylor, Kurt Ingar Draget, Olav Asmund Smidsrod
  • Publication number: 20140155346
    Abstract: The present invention relates to a topical composition, in particular a cosmetic and/or dermatological composition, to be used for preventing and/or treating stretch marks, including, in a physiologically acceptable medium, an effective amount of at least one synthetic polysulfated oligosaccharide having 1 to 4 glycose units, the salts thereof, and/or the derivatives thereof. The invention also relates to a cosmetic method, in particular for treating stretch marks, including at least one step of applying said composition to the skin.
    Type: Application
    Filed: July 12, 2012
    Publication date: June 5, 2014
    Applicants: SOCIETE DE DEVELOPPEMENT ET DE RECHERCHE INDUSTRIELLE, LABORATOIRES URGO
    Inventors: Laurent Apert, Marielle Bouschbacher
  • Publication number: 20140155349
    Abstract: The use of a pharmaceutical regimen to deter in an individual, as the individual ages, the development of a cardiovascular disease (CVD) or Alzheimer's disease or to treat an individual who has CVD or Alzheimer's, the individual ingesting on a daily basis a regimen comprising pharmaceutically effective amounts of magnesium salicylate and naproxen, the amount of the magnesium salicylate being no greater than about 260 mg, and also the use of a pharmaceutical regimen to treat an individual who has Type 2 diabetes, the regimen being ingested daily by the individual and comprising pharmaceutically effective amounts of at least one glucose-lowering drug and magnesium salicylate in an amount no greater than about 260 mg.
    Type: Application
    Filed: June 10, 2013
    Publication date: June 5, 2014
    Inventors: Anthony I. Rozmanith, Jolan S. Rozmanith
  • Publication number: 20140148409
    Abstract: The present invention has an object to provide a fluid for peritoneal dialysis with satisfactory body fluid removability, high biocompatibility, and improved storage stability, and the object is attained by a fluid for peritoneal dialysis containing one or more saccharides selected from cyclonigerosylnigerose, cyclomaltosylmaltose, and L-ascorbic acid 2-glucoside.
    Type: Application
    Filed: January 31, 2014
    Publication date: May 29, 2014
    Applicant: HAYASHIBARA CO. LTD
    Inventors: Hitomi OHTA, Toshiharu HANAYA, Shigeharu FUKUDA, Yoshikatsu MIWA, Toshio MIYAKE
  • Patent number: 8729051
    Abstract: Compositions which include a homotrimer, heterotrimer, homotetramer, and/or heterotetramer of a component such as pentose, hexose, an L or D isomer of a pentose or hexose, a ?-form of a pentose or hexose, oxidized derivatives and mixtures of such compounds are disclosed as agglutination agents. The disclosed compositions are useful for agglutination of enteric pathogens and may be used for selectively controlling and regulating the microbial ecosystem in the gastrointestinal tract of a subject.
    Type: Grant
    Filed: May 29, 2007
    Date of Patent: May 20, 2014
    Assignee: Nutrition Sciences N.V./S.A.
    Inventors: Geert Bruggeman, Katrien Deschepper
  • Publication number: 20140135282
    Abstract: The present application provides a pharmaceutical composition for use in inhibiting recurrence, aggravation or metastasis of liver cancer, in which the pharmaceutical composition comprises at least one compound having a structure of formula (I) and a pharmaceutically acceptable vehicle.
    Type: Application
    Filed: June 9, 2011
    Publication date: May 15, 2014
    Applicant: MEDIGEN BIOTECHNOLOGY CORP
    Inventors: Stanley Chang, Kuan-Lang Lai
  • Publication number: 20140107056
    Abstract: The present invention provides compounds of formula (I): wherein A1, A2, A3 and A4 are independently of one another C—H, C—R5, or nitrogen; B1—B2—B3—B4 is —CH2—C?N—CH2—, —CH2—N—CH2—CH2—, —CH2—C?CH-0- or —CH?C—CH2-0-; G1 is oxygen or sulfur; L is a single bond or C1-C8alkylene; R1 is hydrogen, C1-C8alkyl, C1-C8alkylcarbonyl-, C1-C8alkoxy, C2-C8alkenyl, C2-C8alkynyl, C1-C8alkoxy-C1-C8alkyl, aryl or aryl substituted by one to three R6, or R1 is heterocyclyl or heterocyclyl substituted by one to three R6 or C1-C8alkoxycarbonyl-; R2 is hydrogen, C1-C8haloalkyl or C1-C8alkyl; R3 is C1-C8haloalkyl; R4 is aryl or aryl substituted by one to three R6, or R4 is heterocyclyl or heterocyclyl substituted by one to three R6; Y1 is CR7R8, C?O or C?S; Y2, Y3 and Y4 are independently CR7R8, C=0, C?S, N—R9, O, S, SO or SO2; wherein at least two adjacent ring atoms in the ring formed by Y1, Y2, Y3 and Y4 are heteroatoms; each R7 and R8 is independently hydrogen, halogen, C1-C8alkyl, or C1-C8haloalkyl; and R5, R6, R7, R8 and R9 a
    Type: Application
    Filed: May 30, 2012
    Publication date: April 17, 2014
    Applicant: SYNGENTA PARTICIPATIONS AG
    Inventors: Jerome Yves Cassayre, Peter Renold, Myriem El Qacemi, Thomas Pitterna, Julie Clementine Toueg
  • Publication number: 20140099333
    Abstract: The present invention relates to pyrrolidinone derivatives. The pyrrolidinone derivatives are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of pyrrolidinone derivatives as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: October 8, 2013
    Publication date: April 10, 2014
    Applicant: SANOFI
    Inventors: Lothar SCHWINK, Martin BOSSART, Heiner GLOMBIK, Matthias GOSSEL, Dieter KADEREIT, Thomas KLABUNDE, Thomas MAIER, Siegfried STENGELIN
  • Publication number: 20140100189
    Abstract: A carbohydrate mixture for dietetic foods and pharmaceuticals is provided. The carbohydrate mixture comprises two different, substantially soluble carbohydrate components A and B, which remain undigested in the gastrointestinal tract and enter the large intestine without being resorbed. Carbohydrate component A may comprise at least one monosaccharide or of at least one oligosaccharide (disaccharide to hexasaccharide) or a mixture of two or more of these saccharides. Carbohydrate component B may comprise a polysaccharide (from heptasaccharide onwards) or a mixture of two or more polysaccharides. Carbohydrate component A=5 to 95 wt-% and carbohydrate component B=5 to 95 wt-% of the sum of the carbohydrate components A+B (=100 wt-%), and at least 80 wt-% of the carbohydrates/saccharides of both carbohydrate components have a prebiotic effect. The carbohydrate mixtures have not only a nutritive effect but they also stimulate health-promoting microorganisms present in the natural flora of the large intestine.
    Type: Application
    Filed: October 7, 2013
    Publication date: April 10, 2014
    Applicant: N.V. Nutricia
    Inventors: Gunther SAWATZKI, Bernd Stahl
  • Publication number: 20140088032
    Abstract: The invention relates to a veterinary composition for intramammary administration comprising a combination of an antibacterial agent and a Toll-Like-Receptor (TLR) agonist and to the use of said composition for the treatment of mastitis in lactating ruminants.
    Type: Application
    Filed: May 11, 2012
    Publication date: March 27, 2014
    Inventors: Thomas Simon Ilg, Ralf Warrass, Peter Gerardus Franciscus Cox, Carlos De Sa, Karine Pere
  • Patent number: 8673362
    Abstract: The present invention relates to a composition and uses thereof for treatment of damaged tissue comprising at least one essential amino acid in L form and at least one essential lipid; wherein the composition is administered to a mammal suffering from severe tissue damage. The invention further relates to a composition and uses thereof comprising the mixture of one or more free L-amino acids in which the molar ratio of the free L-amino acids corresponds to the molar ratio of amino components in a mammalian tissue protein; and at least one essential lipid.
    Type: Grant
    Filed: October 24, 2011
    Date of Patent: March 18, 2014
    Assignee: Immunopath Profile, Inc.
    Inventor: Leonard S. Girsh
  • Patent number: 8673878
    Abstract: The invention provides a method of treatment of a female human or non-human subject to enhance cervical mucus penetrability by spermatozoa, which method comprises vaginally applying to said subject an effective amount of a spermicide-free, physiologically tolerable oligouronate.
    Type: Grant
    Filed: October 6, 2006
    Date of Patent: March 18, 2014
    Assignee: NTNU Technology Transfer AS
    Inventors: Catherine Taylor, Kurt Ingar Draget, Olav Asmund Smidsrod
  • Publication number: 20140065062
    Abstract: The present invention relates to a novel family of alkylated halogenated di- and trisaccharides which exhibit pharmaceutical efficacy in the areas of permeation enhancers, anti-microbial effects, anti-fugal effects, facilitation of diagnostic procedures. The invention further includes methods of treatment and diagnostic kits.
    Type: Application
    Filed: November 4, 2013
    Publication date: March 6, 2014
    Inventor: Bahram Memarzadeh